MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-373-1500
Debt
Current Ratio34.89
Quick Ratio34.89
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book9.18
Profitability
Net Income$-11,160,000.00
Net MarginsN/A
Return on Assets-23.07%
Miscellaneous
Employees9
OptionableOptionable
MediciNova (NASDAQ:MNOV) Frequently Asked Questions
What is MediciNova's stock symbol?
MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
How were MediciNova's earnings last quarter?
MediciNova, Inc. (NASDAQ:MNOV) posted its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Zacks' consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.
When is MediciNova's next earnings date?
What price target have analysts set for MNOV?
1 equities research analysts have issued twelve-month price targets for MediciNova's stock. Their predictions range from $22.00 to $22.00. On average, they expect MediciNova's share price to reach $22.00 in the next year. This suggests a possible upside of 124.0% from the stock's current price. View Analyst Price Targets for MediciNova.
What is the consensus analysts' recommendation for MediciNova?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.
Has MediciNova been receiving favorable news coverage?
News headlines about MNOV stock have trended positive on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MediciNova earned a news impact score of 2.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days.
Who are some of MediciNova's key competitors?
Some companies that are related to MediciNova include Pacira Pharmaceuticals (PCRX), Prestige Consumer Healthcare (PBH), Cambrex (CBM), Theravance Biopharma (TBPH), Vanda Pharmaceuticals (VNDA), The Medicines (MDCO), Biohaven Pharmaceutical (BHVN), Aimmune Therapeutics (AIMT), Enanta Pharmaceuticals (ENTA), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Phibro Animal Health (PAHC), Nabriva Therapeutics (NBRV), Wave Life Sciences (WVE) and TherapeuticsMD (TXMD).
Who are MediciNova's key executives?
MediciNova's management team includes the folowing people:
- Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
- Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
- Dr. Kazuko Matsuda M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
- Mr. Geoffrey G. O'Brien, VP & Exec. Officer (Age 50)
- Ms. Carla Reyes, Chief Financial Officer (Age 47)
How do I buy shares of MediciNova?
Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MediciNova's stock price today?
One share of MNOV stock can currently be purchased for approximately $9.82.
How big of a company is MediciNova?
MediciNova has a market capitalization of $394.10 million. The biopharmaceutical company earns $-11,160,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. MediciNova employs 9 workers across the globe.
What is MediciNova's official website?
How can I contact MediciNova?
MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]
MarketBeat Community Rating for MediciNova (NASDAQ MNOV)
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
